Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EG 110A

X
Drug Profile

EG 110A

Alternative Names: EG-110A

Latest Information Update: 01 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EG 427
  • Class Gene therapies; Urologics
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Interstitial cystitis; Neurogenic bladder; Overactive bladder

Most Recent Events

  • 24 Jun 2024 US FDA approves IND application for EG 110A in Overactive bladder and Neurogenic bladder
  • 04 Jan 2024 EG 427announces intention to submit IND to US FDA for EG 110A in first quarter of 2024
  • 04 Jan 2024 EG 427 plans First-in-human phase Ib/IIa trial of non-replicative HSV1-based gene therapy in the treatment of Overactive bladder and Neurogenic bladder in patients with Spinal cord injury
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top